Omeros Stock Lifted By Positive Phase 2 Clinical Data

By: via Benzinga
Omeros Corporation (NASDAQ: OMER) reported positive initial results for its Phase 2 trial of OMS721, a complement inhibitor for renal ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.